NEW YORK – Seneca Therapeutics, a clinical-stage drug developer based in Philadelphia, said it has received positive feedback from the US Food and Drug Administration allowing it to start Phase I/II studies of its SVV-001 in Q2 of 2021.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.